Complete Genomics (GNOM)
Complete Genomics Revenues: 3.908M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
GNOM Revenues Rankings
| Overall | 5th percentile | 4162 of 4425 |
| Sector | 22nd percentile | 366 of 470 in Healthcare |
| Industry | 38th percentile | 81 of 132 in Biotechnology |
GNOM Revenues Range, Past 5 Years
| Minimum | 0.336M | Mar 2010 |
| Maximum | 6.833M | Mar 2011 |
| Average | 3.627M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these GNOM related companies
GNOM News
$MVIS http://stks.co/41SZ In play $MVIS $GNOM $AMRN $ALSN full blog post here http://stks.co/41Sa
about 4 hours ago by LincolnList
about 4 hours ago by LincolnList
$GNOM when you have a lotto you cash in and walk away…. but might buy another ticket some day
about 5 hours ago by Partridge
about 5 hours ago by Partridge
RT $GNOM @EUROCAYMAN C'mon Euro, we all already know that. This just in: Water is wet! Also, no shart Sherlock!
about 5 hours ago by SomeGuy900
about 5 hours ago by SomeGuy900
@EUROCAYMAN re; your link on $GNOM. The gist of that is they are trying to standardize these techniques and approaches.What's your point?
about 6 hours ago by SomeGuy900
about 6 hours ago by SomeGuy900
@ChasinCheddar already up a/h, imo this was nothing but MM scare tactics to get us to sell. Not me, not today, bought more $GNOM
about 8 hours ago by EUROCAYMAN
about 8 hours ago by EUROCAYMAN
$GNOM looks like I screwed up here. O well, it's biotech, this will bounce again for no reason at all. At that time, I will be a seller.
about 8 hours ago by ChasinCheddar
about 8 hours ago by ChasinCheddar
@SomeGuy900 $GNOM you wanna know the real reason ratings exist?So MM that downgrade can buy in on cheaper shares after missing the run up!!
about 8 hours ago by BiopharmaPro
about 8 hours ago by BiopharmaPro
$GNOM Avg 3.01.....should of got out at 3.30 last week. Will continue to be a proud bagholder.
about 10 hours ago by ChasinCheddar
about 10 hours ago by ChasinCheddar
$GNOM @epime7heus agree 100%, i'm holding every share I own, not selling today, this looks like big boyz wanting shares.
about 10 hours ago by EUROCAYMAN
about 10 hours ago by EUROCAYMAN
@johnkelly $GNOM this is not a momo stock for short term trade! this is a long term stock which will be a multibagger in a few years!
about 10 hours ago by BiopharmaPro
about 10 hours ago by BiopharmaPro
Vertex Pharmaceuticals Incorporated, Tractor Supply Company Among Stocks Down on Above-average Volume Tuesday
May 29, 12:32PM Fox Business
May 29, 12:32PM Fox Business
Genetic Technologies and Complete Genomics Strong Performers in a Booming Industry
May 28, 8:20AM Marketwire
May 28, 8:20AM Marketwire
Unusual 11 Mid-Day Movers 05/25: (GNOM) (UPI) (RPRX) Higher; (TLB) (DCTH) (PAY) Lower
May 25, 1:42PM Street Insider
May 25, 1:42PM Street Insider
Morning Movers 05/25: (GNOM) (UPI) (EJ) Higher; (DCTH) (TLB) (GENE) Lower
May 25, 10:39AM Street Insider
May 25, 10:39AM Street Insider
Pre-Open Movers 5/25: (BLOX) (FRO) (QSFT) Higher; (TLB) (ROSG) (DCTH) Lower (more...)
May 25, 9:33AM Street Insider
May 25, 9:33AM Street Insider
Unusual 11 Mid-Day Movers 05/24: (GENE) (GNOM) (SWSH) Higher; (NTAP) (SIG) (LDK) Lower
May 24, 1:03PM Street Insider
May 24, 1:03PM Street Insider
Morning Movers 05/24: (GENE) (GNOM) (P) Higher; (NTAP) (PCX) (TIF) Lower
May 24, 10:27AM Street Insider
May 24, 10:27AM Street Insider
UBS Maintains a 'Neutral' on Complete Genomic (GNOM); Adjusting Numbers After Q1 Review
May 08, 10:12AM Street Insider
May 08, 10:12AM Street Insider
UPDATE: Jefferies Cuts Target to $5 on Complete Genomics; Declining Unit Volume
May 08, 7:34AM Benzinga
May 08, 7:34AM Benzinga
Complete Genomics Schedules First Quarter 2012 Earnings Release and Announces Conference Call
May 03, 8:01AM GlobeNewswire
May 03, 8:01AM GlobeNewswire
UBS Maintains a 'Neutral' on Complete Genomic (GNOM); Deal Visibility Still Low
Mar 09, 11:28AM Street Insider
Mar 09, 11:28AM Street Insider
Complete Genomics Schedules Fourth Quarter and Fiscal Year 2011 Earnings Release and Announces Conference Call
Mar 05, 4:47PM GlobeNewswire
Mar 05, 4:47PM GlobeNewswire
Complete Genomics Announces Formation of Genomic Medicine Advisory Board
Feb 29, 8:00AM GlobeNewswire
Feb 29, 8:00AM GlobeNewswire
Study Published in Journal Nature Suggests New Genomic Pathways for Neuroblastoma
Feb 24, 8:00AM GlobeNewswire
Feb 24, 8:00AM GlobeNewswire
Complete Genomics Co-Authors Paper Demonstrating Impact of Hepatitis B Virus on Liver Cancer Genomes
Feb 23, 8:00AM GlobeNewswire
Feb 23, 8:00AM GlobeNewswire
Complete Genomics Named to MIT's Technology Review Top 50 Innovative Companies List for Third-Consecutive Year
Feb 21, 7:26PM GlobeNewswire
Feb 21, 7:26PM GlobeNewswire
Small-Cap Stock Trade Review: Complete Genomics Report Featured on MicroStockProfit.com
Feb 14, 6:50AM GlobeNewswire
Feb 14, 6:50AM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GNOM | 2.61 | -0.39 | -13.00% | 100.26M |
| GNMK | 4.61 | +0.03 | +0.66% | 93.89M |
| GNK | 3.23 | +0.01 | +0.31% | 141.07M |
| GNI | 65.28 | +2.39 | +3.80% | 94.34M |
| GNE | 7.07 | +0.06 | +0.86% | |
| GNCMA | 6.33 | -0.36 | -5.38% | 295.30M |
| GNC | 39.54 | -0.01 | -0.03% | |
| GNAT | 21.95 | +0.36 | +1.69% | |
| GMXR | 0.95 | +0.03 | +3.26% | 62.81M |
| GMT | 38.98 | +0.31 | +0.80% | 1.811B |
